Indian Pharma API + Bulk Drug Plant MEP — Schedule M 2023 + USFDA 21 CFR 211 + ICH Q7 + WHO TRS 1019
A 500 t/yr Indian pharma API + bulk drug plant demands ₹895 Cr MEP capex with synthesis reactor halls + crystallisation + drying + QC labs + ICH Q1A stability chambers + solvent vapour recovery (> 95 %) + ETP-ZLD with MEE crystalliser. Schedule M 2023 + USFDA 21 CFR 211 + WHO TRS 1019 + ICH Q7 + EU Annex 18 + ISPE govern. Three failures: solvent recovery < 95 % emitting 800-1500 mg/Nm³ vs CPCB 5 limit, stability chamber temperature mapping skipped failing USFDA, ETP without MEE crystalliser causing state PCB closures 2022-2024.
Indian pharma API plant + bulk drug manufacturing framework
India is the worlds 3rd-largest pharma API producer (Dr Reddys + Sun Pharma + Cipla + Aurobindo + Divis + Hetero + Lupin + Torrent + Glenmark + Strides). API plants make bulk active ingredients via fermentation / chemical synthesis. Standards stack — Schedule M revised Dec 2023 + USFDA cGMP 21 CFR 211 + WHO TRS 1019 Annex 3 (APIs) + ICH Q7 (API GMP) + EU EMA Annex 18 + ISPE Baseline Vol 1 (APIs) + ISO 14644 + 14001 + USP 1116 + India Drugs + Cosmetics Rules.
500 t/yr API plant MEP scope — multi-product bulk drugs
| Zone | Activity | Grade | Capex (₹ Cr) |
|---|---|---|---|
| Raw material warehouse | controlled climate | 22 ± 2°C / 60 % RH | 25 |
| Solvent storage tank-farm | flammable + toxic | Class 1 Div 1 | 35 |
| Synthesis reactor hall (kilo-lab) | 100-1500 L glass-lined | D-grade | 85 |
| Synthesis reactor hall (production) | 5000-20000 L SS-316 | C-grade | 185 |
| Crystallisation + filtration | centrifuge + filter-dryer | C-grade | 62 |
| Drying + milling | vacuum dryer + jet mill | C-grade | 45 |
| Packaging + finished product | — | D-grade | 35 |
| QC + microbiology lab | — | ISO 17025 + GLP | 62 |
| Stability chambers (ICH Q1A) | 25°C/60% + 40°C/75% + 30°C/65% | — | 22 |
| HVAC + dehumidification | — | — | 85 |
| Boiler + steam plant | 15 t/hr | IBR | 42 |
| Process cooling water | — | CTI | 25 |
| Solvent vapour recovery (VOC < 5 mg/Nm³) | activated carbon + condenser | CPCB | 62 |
| ETP + ZLD (toxic + AOX) | RO + MEE + crystalliser | CPCB Pharma | 125 |
| Total API plant MEP | — | — | 895 |
Three Indian pharma API plant MEP failures
- Solvent vapour recovery < 95 % — USFDA + CPCB + EU EMA require > 95 % solvent recovery. Indian legacy plants emit 800-1500 mg/Nm³ vs CPCB 5 mg/Nm³ limit. Specify activated carbon + condenser + cryogenic recovery for chlorinated.
- Stability chamber temperature mapping skipped — ICH Q1A + WHO TRS 1019 require chamber mapping with 27 sensor grid + 24-hr trend + door-open recovery. USFDA inspection failure most common. Specify mapping at IQ + annual re-validation.
- ETP ZLD without MEE crystalliser — pharma effluent contains chlorinated + AOX + heavy-metal residue. Standard RO inadequate; need MEE + crystalliser to ZLD per Maharashtra + Telangana + Andhra state pollution control. Many APIs face state PCB closure 2022-2024 for non-compliance.
- Schedule M Drugs + Cosmetics Rules 1945 revised 28 Dec 2023 (India).
- USFDA 21 CFR Part 211 cGMP + Guidance for Industry on APIs 2024.
- WHO Technical Report Series No. 1019 Annex 3 — Good Manufacturing Practices for APIs.
- ICH Q7:2000 + Q1A R2 — GMP for APIs + Stability Testing.
- EU EMA Annex 18 — APIs.
- ISPE Baseline Guide Vol 1 — Active Pharmaceutical Ingredients 2018.
- USP 1116 — Microbiological Control + Monitoring of Aseptic Processing Environments.
- CPCB Pharma Industry Effluent Standards 2022 (ZLD for selected states).